Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC‑7901 cells

Jiang,Tao; Zhang,Hongjun; Liu,Xiguang; Song,Hao; Yao,Ruyong; Li,Jianbin; Zhao,Yuanyuan

doi:10.3892/ol.2016.5293

Effect of oxaliplatin combined with polyenephosphatidylcholine on the proliferation of human gastric cancer SGC‑7901 cells

Authors:
- Tao Jiang
- Hongjun Zhang
- Xiguang Liu
- Hao Song
- Ruyong Yao
- Jianbin Li
- Yuanyuan Zhao
View Affiliations

Affiliations: School of Medicine, Shandong University, Jinan, Shandong 250012, P.R. China, Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Central Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China, Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to Shandong University, Shandong Academy of Medical Sciences, Jinan, Shandong 250117, P.R. China
Published online on: October 19, 2016 https://doi.org/10.3892/ol.2016.5293
Pages: 4538-4546
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Oxaliplatin (L-OHP) is a platinum compound that is widely used to treat certain solid tumors, including gastric tumors. L‑OHP is an effective anti‑cancer treatment; however, its usage increases the probability of patients developing hepatic injury with inflammation, referred to as chemotherapy‑associated steatohepatitis. The present study aimed to evaluate the outcome of L‑OHP treatment combined with polyenephosphatidylcholine (PPC), a major component of essential phospholipids used to treat steatohepatitis, on SGC‑7901 gastric cancer cell proliferation. This would help to determine whether combination therapy with L‑OHP and PPC is clinically beneficial for patients with gastric cancer. The viability of SGC‑7901 cells was verified by an MTT assay; flow cytometry was used to analyze the cell cycle and rates of cell apoptosis; oxidation‑related indicators were measured by spectrophotometry, and the expression of cell cycle‑ and apoptosis‑related proteins was determined by western blotting. The results demonstrated that L‑OHP significantly inhibited SGC‑7901 cell growth in a dose‑ and time‑dependent manner (F=194.193, P<0.01 and F=12.428, P=0.01, respectively). Furthermore, PPC stimulated the growth of SGC‑7901 cells and greatly promoted their apoptosis induced by L‑OHP, which was supported by the upregulation of cytochrome c and the downstream activation of caspases 3 and 9. Finally, following treatment with a combination of PPC and L‑OHP, the expression of cyclins D1 and E was downregulated; however, PPC did not alter the production of reactive oxygen species caused by L‑OHP (P=0.88). The present study determined that the combination of L‑OHP and PPC exerts a synergistic anti‑tumor effect, suggesting that L‑OHP and PPC combination therapy may be used as a treatment for patients with gastric cancer that reduces the side effects of L‑OHP without inhibiting its efficacy.

View Figures

View References

1	Dong CX, Fu JF, Ye XY, Li XF, Zhong X and Yuan Y: Surgical resection of advanced gastric cancer following trastuzumab/oxaliplatin/capecitabine combination therapy. World J Gastroenterol. 20:12355–12358. 2014. View Article : Google Scholar : PubMed/NCBI
2	Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249. 2009. View Article : Google Scholar : PubMed/NCBI
3	Choi IJ, Lee JH, Kim YI, Kim CG, Cho SJ, Lee JY, Ryu KW, Nam BH, Kook MC and Kim YW: Long-term outcome comparison of endoscopic resection and surgery inearly gastric cancer meeting the absolute indication for endoscopic resection. Gastro intest Endosc. 81:333.e1–341.e1. 2015. View Article : Google Scholar
4	Fiteni F, Nguyen T, Vernerey D, Paillard MJ, Kim S, Demarchi M, Fein F, Borg C, Bonnetain F and Pivot X: Cisplatin/gemcitabine or oxaliplatin/gemcitabine in the treatment of advanced biliary tract cancer: A systematic review. Cancer Med. 3:1502–1511. 2014. View Article : Google Scholar : PubMed/NCBI
5	Schumacher JD and Guo GL: Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol. 289:40–47. 2015. View Article : Google Scholar : PubMed/NCBI
6	Jiang Tao, Song Hao, Zhao Yuan-Yuan, Liang Jun, Zhang Hong-Jun and Liu Xi-Guang: Effect of oxaliplatin combined with polyenephosphatidylcholine on proliferation of gastric cancer cells. Chinese Journal of Cancer Prevention and Treatment. 13:41–44. 2014.
7	Cao M, Li X, Zhang B, Han S, Yang Y, Zhou B and Zhang Y: The effect of polyene phosphatidyl choline intervention on nonalcoholic steatohepatitis and related mechanism. Am J Transl Res. 8:2325–2330. 2016.PubMed/NCBI
8	Kim HS, Kim JH, Kim HJ, Jang HJ, Kim JB, Kim JW, Jung SY, Kim BC, Yang DH, Park S, et al: Oxaliplatin, 5-fluorouracil and leucovorin (modified FOLFOX-6) as first-line chemotherapy for advanced gastric cancer patients with poor performance status. Oncol Lett. 3:425–428. 2012.PubMed/NCBI
9	Rosati G, Ferrara D and Manzione L: New perspectives in the treatment of advanced or metastatic gastric cancer. World J Gastroenterol. 15:2689–2692. 2009. View Article : Google Scholar : PubMed/NCBI
10	Koizumi W, Takiuchi H, Yamada Y, Boku N, Fuse N, Muro K, Komatsu Y and Tsuburaya A: Phase II study of oxaliplatin plus S-1 as first-line treatment for advanced gastric cancer (G-SOX study). Ann Oncol. 21:1001–1005. 2010. View Article : Google Scholar : PubMed/NCBI
11	Park I, Lee JL, Ryu MH, Chang HM, Kim TW, Sym SJ, Lee SS, Jang G, Yoo C, Bae KS and Kang YK: Phase I/II and pharmacokinetic study of S-1 and oxaliplatin in previously untreated advanced gastric cancer. Cancer Chemother Pharmacol. 65:473–480. 2010. View Article : Google Scholar : PubMed/NCBI
12	Choti MA: Chemotherapy-associated hepatotoxicity: Do we need to be concerned? Ann Surg Oncol. 16:2391–2394. 2009. View Article : Google Scholar : PubMed/NCBI
13	Malaguarnera M, Di RM, Nicoletti F and Malaguarnera L: Molecular mechanisms involved in NAFLD progression. J Mol Med (Berl). 87:679–695. 2009. View Article : Google Scholar : PubMed/NCBI
14	Okyama W, Tanaka N, Nakajima T, Tanaka E, Kiyosawa K, Gonzalez FJ and Aoyama T: Polyenephosphatidylcholine prevents alcoholic liver disease in PPARalpha-null mice through attenuation of increases in oxidative stress. J Hepatol. 50:1236–1246. 2009. View Article : Google Scholar : PubMed/NCBI
15	Lieber CS, Robins SJ, Li J, DeCarli LM, Mak KM, Fasulo JM and Leo MA: Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology. 106:152–159. 1994. View Article : Google Scholar : PubMed/NCBI
16	Cao Q, Mak KM and Lieber CS: Dilinoleoylphosphatidylcholine decreases acetaldehyde-induced TNF-alpha generation in Kupffer cells of ethanol-fed rats. Biochem Biophys Res Commun. 299:459–464. 2002. View Article : Google Scholar : PubMed/NCBI
17	Cao Q, Mak KM and Lieber CS: DLPC and SAMe combined prevent leptin-stimulated TIMP-1 production in LX-2 human hepatic stellate cells by inhibiting HO-mediated signal transduction. Liver Int. 26:221–231. 2006. View Article : Google Scholar : PubMed/NCBI
18	Chou TC: Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
19	Esmaeili MA, Abagheri-Mahabadi N, Hashempour H, Farhadpour M, Gruber CW and Ghassempour A: Viola plant cyclotide vigno 5 induces mitochondria-mediated apoptosis viacytochrome C release and caspases activation in cervical cancer cells. Fitoterapia. 109:162–168. 2016. View Article : Google Scholar : PubMed/NCBI
20	Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E and Boise LH: Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 14:322013. View Article : Google Scholar : PubMed/NCBI
21	Saito H, Osaki T, Murakami D, Sakamoto T, Kanaji S, Tatebe S, Tsujitani S and Ikeguchi M: Effect of age on prognosis in patients with gastric cancer. ANZ J Surg. 76:458–461. 2006. View Article : Google Scholar : PubMed/NCBI
22	Yoon H and Kim N: Diagnosis and management of high risk group for gastric cancer. Gut Liver. 9:5–17. 2015. View Article : Google Scholar : PubMed/NCBI
23	Glimelius B, Ekström K, Hoffman K, Graf W, Sjödén PO, Haglund U, Svensson C, Enander LK, Linné T, Sellström H and Heuman R: Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol. 8:163–168. 1997. View Article : Google Scholar : PubMed/NCBI
24	Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, et al: Role of chemotherapy for advanced/recurrent gastric cancer: An individual-patient-data meta-analysis. Eur J Cancer. 49:1565–1577. 2013. View Article : Google Scholar : PubMed/NCBI
25	Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crinò L, Benedetti G, Evangelista W, Fanchini L, et al: Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol. 25:1670–1676. 2007. View Article : Google Scholar : PubMed/NCBI
26	Al-Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, et al: Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: A study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 26:1435–1442. 2008. View Article : Google Scholar : PubMed/NCBI
27	Nordberg J and Arnér ES: Reactive oxygen species, antioxidants and the mammalian thioredoxin system. Free Radic Biol Med. 31:1287–1312. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zeng L, Li Y, Li T, Cao W, Yi Y, Geng W, Sun Z and Xu H: Selenium-platinum coordination compounds as novel anticancer drugs: Selectively killing cancer cells via a reactive oxygen species (ROS)-mediated apoptosis route. Chem Asian J. 9:2295–2302. 2014. View Article : Google Scholar : PubMed/NCBI
29	Lee DJ and Kang SW: Reactive oxygen species and tumor metastasis. Mol Cells. 35:93–98. 2013. View Article : Google Scholar : PubMed/NCBI
30	Atmaca M, Kuloglu M, Tezcan E and Ustundag B: Antioxidant enzyme and malondialdehyde levels in patients with social phobia. Psychiatry Res. 159:95–100. 2008. View Article : Google Scholar : PubMed/NCBI
31	Singh N, Zaidi D, Shyam H, Sharma R and Balapure AK: Polyphenols sensitization potentiates susceptibility of MCF-7 and MDA MB-231 cells to Centchroman. PLoS One. 7:e377362012. View Article : Google Scholar : PubMed/NCBI
32	Culy CR, Clemett D and Wiseman LR: Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 60:895–924. 2000. View Article : Google Scholar : PubMed/NCBI
33	Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG and Strasberg SM: Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg. 200:845–853. 2005. View Article : Google Scholar : PubMed/NCBI
34	Horejsová M and Urban J: The effect of polyene phosphatidylcholine (Essentiale forte) in the treatment of liver steatosis and ultrasound findings-preliminary study. Cas Lek Cesk. 133:366–369. 1994.(In Czech). PubMed/NCBI
35	Su HL, Zhu YX, Gao ZJ, Dong XY, Zhu JY, Lei WR, Zhang Y and Han Y: Efficacy comparison between bicyclol and polyene phosphatidylcholine treatments for the patients with nonalcoholic fatty liver disease. Zhonghua Gan Zang Bing Za Zhi. 9:552–553. 2011.(In Chinese).
36	Dragovich T, Rudin CM and Thompson CB: Signal transduction pathways that regulate cell survival and cell death. Oncogene. 17:3207–3213. 1998. View Article : Google Scholar : PubMed/NCBI
37	Gross A, McDonnell JM and Korsmeyer SJ: BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 13:1899–1911. 1999. View Article : Google Scholar : PubMed/NCBI
38	Liu X, Kim CN, Yang J, Jemmerson R and Wang X: Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c. Cell. 86:147–157. 1996. View Article : Google Scholar : PubMed/NCBI
39	Zou H, Henzel WJ, Liu X, Lutschg A and Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell. 90:405–413. 1997. View Article : Google Scholar : PubMed/NCBI
40	Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A and Nagata S: A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature. 391:43–50. 1998. View Article : Google Scholar : PubMed/NCBI
41	Almeida A: Regulation of APC/C-Cdh1 and its function in neuronal survival. Mol Neurobiol. 46:547–554. 2012. View Article : Google Scholar : PubMed/NCBI
42	Zhang K and Kumar R: Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem Biophys Res Commun. 200:522–528. 1994. View Article : Google Scholar : PubMed/NCBI
43	Hossain Z, Konishi M, Hosokawa M and Takahashi K: Effect of polyunsaturated fatty acid-enriched phosphatidylcholine and phosphatidylserine on butyrate-induced growth inhibition, differentiation and apoptosis in Caco-2 cells. Cell Biochem Funct. 24:159–165. 2006. View Article : Google Scholar : PubMed/NCBI
44	Raffy S and Teissié J: Control of lipid membrane stability by cholesterol content. Biophys J. 76:2072–2080. 1999. View Article : Google Scholar : PubMed/NCBI